This was a phase 2 clinical trial and, therefore, did not evaluate long-term, post-treatment serum LH or T levels or ovulation; nonetheless, it demonstrated that the kisspeptin-NKB system is a promising therapeutic target to lower LH and T in PCOS women. This evidence concerns the gene TAC3 and polycystic ovary syndrome.